Literature DB >> 24878386

Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.

Swapnil J Dengale1, Om Prakash Ranjan2, Syed Sajjad Hussen3, B S M Krishna3, Prashant B Musmade3, G Gautham Shenoy4, Krishnamurthy Bhat3.   

Abstract

The aim of this study was to stabilize the amorphous form of Ritonavir (RTV) a BCS class-II drug with known amorphous stabilizing small molecule Indomethacin (IND) by co-amorphous technology. The co-amorphous samples were prepared by solvent evaporation technique in the molar ratios RTV:IND (2:1), RTV:IND (1:1), RTV:IND (1:2) and their amorphous nature was confirmed by XRPD, DSC and FT-IR. Physical stability studies were carried out at temp 25°C and 40°C for maximum up to 90 days under dry conditions. Solubility and dissolution testing were carried out to investigate the dissolution advantage of prepared co-amorphous systems. The amorphous mixtures of all tested molar ratios were found to become amorphous after solvent evaporation. The same was confirmed by detecting halo pattern in diffractograms of co-amorphous mixtures. The Tg values of all three systems were found to be more than 40°C, the highest being 51.88°C for RTV:IND (2:1) system. Theoretical Tg values were calculated by Gordon-Taylor equation. Insignificant deviation of theoretical Tg values from that of practical one, corroborated by FT-IR studies showed no evidence of intermolecular interactions between RTV and IND. Almost 3-folds increase in the solubility for both amorphous RTV and IND was found as compared to their respective crystalline counterparts. The study demonstrated significant increase in the dissolution rate as well as increase in the total amount of drug dissolved for amorphous RTV, however it failed to demonstrate any significant improvement in the dissolution behavior of IND.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphous forms; Dissolution; Indomethacin; Ritonavir; Solubility

Mesh:

Substances:

Year:  2014        PMID: 24878386     DOI: 10.1016/j.ejps.2014.05.015

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  17 in total

1.  New Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin.

Authors:  Manoela K Riekes; Axel Engelen; Bernard Appeltans; Patrick Rombaut; Hellen K Stulzer; Guy Van den Mooter
Journal:  Pharm Res       Date:  2016-02-08       Impact factor: 4.200

Review 2.  Recent Advances in Enhancement of Dissolution and Supersaturation of Poorly Water-Soluble Drug in Amorphous Pharmaceutical Solids: A Review.

Authors:  Qin Shi; Fang Li; Stacy Yeh; Sakib M Moinuddin; Junbo Xin; Jia Xu; Hao Chen; Bai Ling
Journal:  AAPS PharmSciTech       Date:  2021-12-10       Impact factor: 3.246

3.  Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr-/-Mice.

Authors:  Shamuha Bahetibieke; Sakib M Moinuddin; Asiya Baiyisaiti; Xiaoang Liu; Jie Zhang; Guomin Liu; Qin Shi; Ankang Peng; Jun Tao; Chang Di; Ting Cai; Rong Qi
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

4.  A Comparative Study of the Pharmaceutical Properties between Amorphous Drugs Loaded-Mesoporous Silica and Pure Amorphous Drugs Prepared by Solvent Evaporation.

Authors:  Arif Budiman; Diah Lia Aulifa
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-09

5.  A Strategy for Co-former Selection to Design Stable Co-amorphous Formations Based on Physicochemical Properties of Non-steroidal Inflammatory Drugs.

Authors:  Hiroshi Ueda; Noriyuki Muranushi; Satoshi Sakuma; Yasuo Ida; Takeshi Endoh; Kazunori Kadota; Yuichi Tozuka
Journal:  Pharm Res       Date:  2015-12-24       Impact factor: 4.200

6.  Pharmaceutical Co-Crystals, Salts, and Co-Amorphous Systems: A Novel Opportunity of Hot Melt Extrusion.

Authors:  Sagar Narala; Dinesh Nyavanandi; Priyanka Srinivasan; Preethi Mandati; Suresh Bandari; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2020-11-09       Impact factor: 3.981

7.  A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide.

Authors:  Meiling Su; Yanming Xia; Yajing Shen; Weili Heng; Yuanfeng Wei; Linghe Zhang; Yuan Gao; Jianjun Zhang; Shuai Qian
Journal:  RSC Adv       Date:  2020-01-02       Impact factor: 4.036

Review 8.  Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.

Authors:  Anna Karagianni; Kyriakos Kachrimanis; Ioannis Nikolakakis
Journal:  Pharmaceutics       Date:  2018-07-19       Impact factor: 6.321

9.  Liquisolid pellets: A pharmaceutical technology strategy to improve the dissolution rate of ritonavir.

Authors:  Brenda De Espíndola; André O'Reilly Beringhs; Diva Sonaglio; Hellen Karine Stulzer; Marcos Antônio Segatto Silva; Humberto Gomes Ferraz; Bianca Ramos Pezzini
Journal:  Saudi Pharm J       Date:  2019-04-03       Impact factor: 4.330

10.  Amorphous solid dispersion formation via solvent granulation - A case study with ritonavir and lopinavir.

Authors:  Niraj S Trasi; Sonal Bhujbal; Qi Tony Zhou; Lynne S Taylor
Journal:  Int J Pharm X       Date:  2019-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.